Anton K. Peresada, D. Dundua, A. Kedrova, Irina N. Oleinikova, Anna V. Masterkova
{"title":"关于接受心脏毒性化疗的癌症患者心脏保护疗法的现代观点","authors":"Anton K. Peresada, D. Dundua, A. Kedrova, Irina N. Oleinikova, Anna V. Masterkova","doi":"10.17816/clinpract567924","DOIUrl":null,"url":null,"abstract":"Background: Cancer patients receiving high doses of cardiotoxic combined anticancer drugs have an increased risk of cardiovascular complications. During treatment, patients may experience complications from the cardiovascular system, in particular chronic heart failure (CHF). Without the necessary laboratory and instrumental control, it is impossible to predict in advance the development of heart failure, which often complicates chemotherapy, and, in some cases necessitates cancellation of life-saving anticancer therapy. It turned out that timely cardioprotection, a drug intervention aimed at preventing myocardial dysfunction in cancer patients, can prevent the development of heart failure. Aim: The purpose of this review is to briefly reflect the mechanisms of cardiotoxicity in various chemotherapy regimens, as well as the current possibilities of cardioprotection in cancer patients receiving cardiotoxic chemotherapy","PeriodicalId":508133,"journal":{"name":"Journal of Clinical Practice","volume":"2 1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A modern view on cardioprotective therapy in cancer patients receiving cardiotoxic chemotherapy\",\"authors\":\"Anton K. Peresada, D. Dundua, A. Kedrova, Irina N. Oleinikova, Anna V. Masterkova\",\"doi\":\"10.17816/clinpract567924\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Cancer patients receiving high doses of cardiotoxic combined anticancer drugs have an increased risk of cardiovascular complications. During treatment, patients may experience complications from the cardiovascular system, in particular chronic heart failure (CHF). Without the necessary laboratory and instrumental control, it is impossible to predict in advance the development of heart failure, which often complicates chemotherapy, and, in some cases necessitates cancellation of life-saving anticancer therapy. It turned out that timely cardioprotection, a drug intervention aimed at preventing myocardial dysfunction in cancer patients, can prevent the development of heart failure. Aim: The purpose of this review is to briefly reflect the mechanisms of cardiotoxicity in various chemotherapy regimens, as well as the current possibilities of cardioprotection in cancer patients receiving cardiotoxic chemotherapy\",\"PeriodicalId\":508133,\"journal\":{\"name\":\"Journal of Clinical Practice\",\"volume\":\"2 1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17816/clinpract567924\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17816/clinpract567924","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A modern view on cardioprotective therapy in cancer patients receiving cardiotoxic chemotherapy
Background: Cancer patients receiving high doses of cardiotoxic combined anticancer drugs have an increased risk of cardiovascular complications. During treatment, patients may experience complications from the cardiovascular system, in particular chronic heart failure (CHF). Without the necessary laboratory and instrumental control, it is impossible to predict in advance the development of heart failure, which often complicates chemotherapy, and, in some cases necessitates cancellation of life-saving anticancer therapy. It turned out that timely cardioprotection, a drug intervention aimed at preventing myocardial dysfunction in cancer patients, can prevent the development of heart failure. Aim: The purpose of this review is to briefly reflect the mechanisms of cardiotoxicity in various chemotherapy regimens, as well as the current possibilities of cardioprotection in cancer patients receiving cardiotoxic chemotherapy
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
